Always verify pricing and state availability on the provider's website before signing up.How our reviews work →
GoodRx (Foundayo + Zepbound KwikPen) vs Ro
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
8.4
GoodRx (Foundayo + Zepbound KwikPen)
Best for self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies★★★★☆4.2
Starting at $149/mo
FoundayoZepbound KwikPenBrandSelf-Pay Discount Card
Visit GoodRx (Foundayo + Zepbound KwikPen) →7.9
Ro
Best for broadest GLP-1 formulary including Foundayo on day-one of launch★★★★☆4
Starting at $149/mo
FoundayoSemaglutideTirzepatideWegovy
Visit Ro →Side-by-Side Comparison
| Feature | GoodRx (Foundayo + Zepbound KwikPen) | Ro |
|---|---|---|
| Overall Score | ✓8.4/10 | 7.9/10 |
| Starting Price | $149/mo | $149/mo |
| Editorial Rating | ✓4.2 ★ /5 | 4 ★ /5 |
| Features | 6 features | ✓7 features |
| States Available | ✓50 | 0 |
| Compounded | — | — |
| Brand Name | ✓ Yes | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
GoodRx (Foundayo + Zepbound KwikPen)
Pros
- ✓$149/month self-pay price for FDA-approved brand-name Foundayo (orforglipron) — matches the lowest available discounted cash price at launch and is dramatically cheaper than typical retail brand-GLP-1 pricing
- ✓$299/month self-pay for FDA-approved Zepbound KwikPen — significantly under the typical Lilly cash list price
- ✓Honored at 70,000+ US pharmacies nationwide — by far the largest brick-and-mortar redemption network of any GLP-1 distribution channel we cover
- ✓No telehealth membership fee — you bring your own prescription and present the discount card at the pharmacy counter
- ✓Brand-name FDA-approved medication, not compounded — no compounding-pharmacy quality variability or FDA non-evaluation disclaimer
- ✓Pharmaceutical manufacturer-direct pricing model — Lilly is delivering the discounted cash price directly through GoodRx, not a third-party negotiation
Cons
- ✗Requires a valid prescription — GoodRx is a discount card, not a telehealth provider. You still need a clinician to write the script (your existing PCP, an endocrinologist, or a separate telehealth visit)
- ✗Self-pay only — does not coordinate with insurance benefits or apply toward insurance deductibles
- ✗Pricing applies only to the lowest Foundayo dose at the headline number; higher doses may carry different pricing not disclosed in the launch
- ✗Does not include compounded GLP-1s — if you want compounded semaglutide or tirzepatide, this is not the channel
- ✗GoodRx is publicly traded (NASDAQ: GDRX) and pricing is subject to change as Lilly's manufacturer-sponsored coupon program evolves
Ro
Pros
- ✓Most comprehensive GLP-1 formulary in telehealth — compounded semaglutide, brand-name Wegovy, brand-name Zepbound, and the new oral Foundayo (orforglipron) all available on one platform
- ✓Among the first telehealth providers to launch Foundayo on day one of the Lilly partner rollout (April 9 2026)
- ✓Clinician-led plan selection — 'patients connect with a licensed provider and, if appropriate, determine which GLP-1 is the best option based on their insurance coverage, the cost, and their unique clinical needs and health goals'
- ✓Nationwide delivery network — Ro reports having served patients in 'nearly every single county in the United States, including 99% of primary care deserts'
- ✓Both cash-pay and insurance-eligible options under one roof
Cons
- ✗Foundayo on Ro requires a recurring membership in addition to the $149/mo cash drug price — total monthly cost is higher than the headline number
- ✗Specific Foundayo dose-tier pricing above the lowest dose not publicly disclosed in the launch announcement — needs intake to confirm
- ✗State availability and pharmacy partners not itemized publicly — requires signup intake to verify
- ✗Like all telehealth GLP-1 providers, Ro charges separately for the program (membership) and the medication; users sometimes confuse the bundled vs. unbundled pricing models
Our Verdict
Winner: GoodRx (Foundayo + Zepbound KwikPen)Score: 8.4/10
GoodRx (Foundayo + Zepbound KwikPen) edges out Ro with a higher overall score of 8.4/10 and is particularly strong for self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies. Ro remains a solid alternative, especially if you're looking for broadest GLP-1 formulary including Foundayo on day-one of launch.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.